Related Experiment Videos
Targeted proapoptotic LHRH-BH3 peptide
1Department of Pharmaceutics, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, New Jersey, USA.
Purpose:
The purpose of this work was to construct and evaluate a novel targeted proapoptotic peptide for cancer treatment.
Methods:
The peptide consisted of luteinizing hormone-releasing hormone (LHRH) as a targeting moiety specific to LHRH receptors and a synthetic BCL-2 homology 3 (BH3) domain peptide as an apoptosis inducer and a suppressor of antiapoptotic cellular defense. Anticancer activity of the peptide was evaluated on different cancer cell lines.
Results:
The targeting receptor to LHRH peptide is overexpressed in several cancer cell lines but is not expressed in healthy human visceral organs. LHRH and BH3 peptides when applied separately did not demonstrate cellular toxicity. In contrast, the LHRH-BH3 peptide was toxic in several cancer cell lines. Coincubation of LHRH and LHRH-BH3 peptides significantly decreased cytotoxicity of the latter. It was found that the LHRH-BH3 peptide induced apoptosis by simultaneous inhibition of the antiapoptotic function of BCL-2 protein family and activation of caspase-dependent signaling pathway.
Conclusions:
The proposed anticancer proapoptotic LHRH-BH3 peptide simultaneously affects two molecular targets: 1) extracellular cancer-specific LHRH receptors and 2) the intracellular controlling mechanisms of apoptosis. The results of this work may be used to design novel approaches for the treatment of various cancers.
Insights
A novel targeted proapoptotic peptide, LHRH-BH3, effectively induces cancer cell death by targeting LHRH receptors and inhibiting antiapoptotic proteins. This peptide shows promise for developing new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Cancer cells often overexpress LHRH receptors.
- Targeting cancer-specific receptors can enhance drug delivery.
- Apoptosis pathways are crucial in cancer development and treatment.
Purpose of the Study:
- To construct and evaluate a novel targeted proapoptotic peptide for cancer treatment.
- To assess the anticancer activity of a peptide combining LHRH targeting and BH3 apoptosis induction.
- To investigate the molecular mechanisms of the peptide's anticancer effects.
Main Methods:
- Conjugation of luteinizing hormone-releasing hormone (LHRH) peptide with a synthetic BCL-2 homology 3 (BH3) domain peptide.
- Evaluation of the synthesized LHRH-BH3 peptide's anticancer activity on various cancer cell lines.
- Analysis of apoptosis induction, caspase activation, and BCL-2 protein family inhibition.
Main Results:
- LHRH receptors are overexpressed on cancer cells but not healthy organs.
- LHRH-BH3 peptide demonstrated significant cytotoxicity in cancer cell lines, unlike individual components.
- The peptide induced apoptosis via simultaneous inhibition of BCL-2 family proteins and activation of caspase pathways.
Conclusions:
- The LHRH-BH3 peptide represents a novel anticancer agent targeting both extracellular cancer-specific receptors and intracellular apoptosis mechanisms.
- This dual-targeting strategy offers a promising new approach for the treatment of various cancers.
- Further development of this peptide could lead to innovative cancer therapies.